CSE: BUX | OTCQB: BMKDF

BioMark™ Diagnostics

Dr. Ian Smith Joins BioMark’s Board of Directors

Vancouver, British Columbia – (December 5th, 2017)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company.

Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Smith to our board. His achievements in medical research space will be a major asset to BioMark.  Dr. Smith’s diagnostic expertise, leadership and research experience brings depth and practicality as we begin to commercialize and position our technology for different oncology applications and potential linkages with strategic distribution partners.”

About Dr. Ian C.P. Smith, O.C., OFS, Ph.D., D.Sc., FRS(C)

Dr. Ian Smith is the Chair of CIMTEC’s Board of Directors. Dr. Smith began his National Research Council (NRC) career in Ottawa as a Research Officer specializing in magnetic resonance. In 1987, he became Director General of the NRC Institute for Biological Sciences, Ottawa.  In 1992, he founded the Institute for Biodiagnostics in Winnipeg as its first Director General.  The Institute focuses on the development and commercialization of medical devices for the non-invasive diagnosis of disease.

Dr. Smith is dedicated to early detection and treatment of disease and using this knowledge to advance the state of medicine and the economy. He is a passionate mover for the commercialization of the products of research, and has started nine companies with a present value of $300 million. In 2013, he retired from NRC to help build a spin-off company, Innovative Biodiagnostics, specializing in tests for colon cancer and breast cancer.

He was appointed Officer of the Order of Canada in 2008 for his leadership in the advancement, development and commercialization of Canada’s diagnostic technologies, notably magnetic resonance imaging, in the field of health care. In addition, Dr. Smith received the 2008 Outstanding Achievement Award of the Public Service of Canada, presented to individuals who have displayed long-term excellence throughout their careers in Canada’s public service. He was awarded the Queen’s Gold (2002) and Diamond (2012) Jubilee Medals for his contributions.

https://www.aexcea.com/Press Release – Dr. Ian Smith Joins BioMark’s Board of Directors

Contact BioMark Diagnostics

Canadian Stock Exchange

CSE: BUX
BioMark Diagnostics Inc.
$0.55
+0.00 (0.00%)
Last updated: Market close • Delayed quote
View Live Quote on Yahoo Finance →

OTC Markets

OTCQB: BMKDF
BioMark Diagnostics Inc.
$0.40
+0.00 (0.00%)
Last updated: Market close • Delayed quote
View Live Quote on Yahoo Finance →

Frankfurt Stock Exchange

FSE: 20B
BioMark Diagnostics Inc.
€0.36
+0.00 (0.00%)
Last updated: Market close • Delayed quote
View Live Quote on Yahoo Finance →

Share This Post

Facebook
X
LinkedIn
Reddit
VK
StumbleUpon
Telegram
XING
WhatsApp
Threads
Email
Print

Related News

Sign up for the latest BioMark news